Free Trial
LON:ROQ

Roquefort Therapeutics (ROQ) Share Price, News & Analysis

Roquefort Therapeutics logo
GBX 1.73 +0.03 (+1.76%)
As of 05/2/2025 09:50 AM Eastern

About Roquefort Therapeutics Stock (LON:ROQ)

Key Stats

Today's Range
1.60
1.75
50-Day Range
1.52
2.40
52-Week Range
1.40
6.78
Volume
573,383 shs
Average Volume
2.63 million shs
Market Capitalization
£2.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Receive ROQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ROQ Stock News Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
TG Therapeutics, Inc. (TGTX)
See More Headlines

ROQ Stock Analysis - Frequently Asked Questions

Roquefort Therapeutics' stock was trading at GBX 4.10 on January 1st, 2025. Since then, ROQ stock has decreased by 57.8% and is now trading at GBX 1.73.
View the best growth stocks for 2025 here
.

Roquefort Therapeutics plc (LON:ROQ) issued its earnings results on Wednesday, April, 30th. The company reported ($0.75) earnings per share for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative trailing twelve-month return on equity of 29.57%.

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF).

Company Calendar

Last Earnings
4/30/2025
Today
5/05/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ROQ
CIK
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-1,519,059.52
Net Margins
-57,057.07%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2,662.35
Cash Flow
GBX 1.16 per share
Price / Cash Flow
1.49
Book Value
GBX 3.82 per share
Price / Book
0.45

Miscellaneous

Free Float
N/A
Market Cap
£2.20 million
Optionable
Not Optionable
Beta
0.05
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (LON:ROQ) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners